Business
TME Pharma: Termination of the Liquidity Contract
BERLIN, July 08, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical stage biotechnology company focused on developing novel therapies for treatment of cancer and eye diseases, announced today the termination of the liquidity contract entered into with the brokerage firm INVEST SECURITIES (the "Contract"). The termination became effective on July 7, 2025 after market close.
About this update from Tme Pharma N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":313,"url":"https://media.zenfs.com/en/business-wire.com/dd74efe52c538645472983e7402e5d79"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wTO7PBtdSZKpiMhlzSMg4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/dd74efe52c538645472983e7402e5d79","width":960,"height":300},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/hen49ln6nbG7YMsQBCz4vA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD02MjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/dd74efe52c538645472983e7402e5d79","width":1000,"height":313}},"lazy":false},{"type":"text","content":"BERLIN, July 08, 2025--(BUSINESS WIRE)--Regulatory News:","length":56,"tagName":"p"},{"type":"text","content":"TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical stage biotechnology company focused on developing novel therapies for treatment of cancer and eye diseases, announced today the termination of the liquidity contract entered into with the brokerage firm INVEST SECURITIES (the "Contract"). The termination became effective on July 7, 2025 after market close.","length":376,"tagName":"p"},{"type":"text","content":"This decision is part of a broader cost optimization plan following the company’s refinancing and organizational restructuring in the first half of 2025. Costs have been brought down drastically and the organization will continue to reduce operational costs to extend preserve cash. The termination of the liquidity-contract is another measure to limit costs. Given the improved trading volume and healthy liquidity of TME Pharma’s shares, the Company considers the liquidity contract no longer necessary.","length":505,"tagName":"p"},{"type":"text","content":"Upon closing of the liquidity account, the following resources appeared on the liquidity account:","length":97,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"85,812 shares","length":13,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"€14.974,69 in cash","length":18,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":31,"olType":false},{"type":"text","content":"As of the latest report, dated June 30, 2025, the following resources appeared on the liquidity...